Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NKTR vs VOR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NKTR Captures Overall Composite Edge (61.1 BUY vs 57.8 HOLD), While VOR Leads 3–2 on Growth & Valuation Pillars

NKTR Overall Winner 6-Pillar Tally: NKTR 2 – 3 VOR (1 Tie) Matrix Metrics: NKTR 5 – 5 VOR

As of Nov 16, 2026, Nektar Therapeutics (NKTR) captures the overall head-to-head institutional edge over Vor Biopharma Inc. (VOR) on higher Unified Composite conviction (61.1/100 BUY vs. 57.8/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while VOR wins 3–2 across the 6-pillar growth and valuation breakdown. NKTR trades at $36.57 (34.0x Forward P/E, -239.3% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: NKTR earns the overall head-to-head edge with a stronger Unified Composite Score (61.1/100 BUY vs. VOR 57.8/100 HOLD) and 1.10β · 48% Vol risk profile, whereas VOR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NKTR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NKTR vs VOR
NKTR NASDAQ Head-to-Head Winner
Nektar Therapeutics
Pharmaceutical Preparations
$36.57
-1.88% 1D
Market Cap $1.3B
TTM Revenue $55M
Forward P/E 34.0x
Beta / 30D Vol 1.10β · 48% Vol
Unified Composite Score
61.1 / 100 BUY
Tech 47.0 Fund 58.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.3%), weak momentum, RSI 35
RSI-14: 35.3 · SMA20: $37.84 · SMA50: $47.72
VOR NASDAQ
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$19.26
-0.82% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.91β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87

6-Pillar Scorecard Institutional Category Breakdown (NKTR 2 – 3 VOR)

Columns: Metric · NKTR · VOR
1. Valuation Multiples NKTR
Forward P/E 34.0x N/M
Trailing P/E 34.0x 0.1x
PEG Ratio 0.31x N/M
EV / Revenue 24.0x N/M
2. Growth & Scale NKTR
Revenue Growth (YoY) -9.3% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $55M N/A
Market Cap $1.3B $1.2B
3. Profitability & Quality VOR
Gross Margin 100.0% N/A
Operating Margin -239.3% 0.0%
Net Profit Margin -287.8% 0.0%
Return on Equity (ROE) -35.8% -125.4%
4. Balance Sheet & Cash Flow VOR
Cash Generation (TTM) -$234M -$1.63B
Cash Flow Margin N/A N/A
Net Cash / Leverage $39M Net Debt (0.09x D/E) $1.04B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 76.9% (5th %ile) 127.0% (6th %ile)
Put/Call OI Skew N/A 2.03x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NKTR (5) vs VOR (5)
Institutional Metric NKTR VOR Criterion Row Edge
Market Capitalization
Scale
$1.3B $1.2B Larger Scale NKTR
Trailing P/E Ratio
Valuation
34.0x 0.1x Lower Multiple VOR
Forward P/E Ratio
Valuation
34.0x N/M Lower Multiple NKTR
Revenue Growth (YoY)
Growth
-9.3% +0.0% Higher Growth VOR
Operating Margin (TTM)
Profitability
-239.3% 0.0% Higher Margin VOR
Net Profit Margin
Profitability
-287.8% 0.0% Higher Margin VOR
Return on Equity (ROE)
Capital Efficiency
-35.8% -125.4% Higher ROE NKTR
52-Week Range Position
Momentum
4% ($33–$109) 65% ($6–$26) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
1.10β · 48% Vol 1.91β · 61% Vol Lower Realized Risk NKTR
Unified Institutional Score
Composite Signal
61.1 / 100 (BUY) 57.8 / 100 (HOLD) Higher Composite NKTR
Trailing 12M Revenue (USD)
Operating Scale
$55M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.31x PEG · 24.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$234M ($39M Net Debt (0.09x D/E)) -$1.63B ($1.04B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +4.61 pp
NKTR: +2.21% · VOR: +6.82%
3M Horizon VOR +33.07 pp
NKTR: -50.34% · VOR: -17.27%
6M Horizon VOR +82.87 pp
NKTR: -46.56% · VOR: +36.31%
1Y Horizon VOR +129.76 pp
NKTR: -32.22% · VOR: +97.54%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NKTR vs VOR. Trailing 12-month operating profitability (NKTR -239.3% vs VOR 0.0%) and valuation multiples (NKTR 34.0x vs VOR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

NKTR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$55M
Gross Margin100.0%
Op. Margin-239.3%
ROE / Fwd P/E-35.8% · 34.0x
VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NKTR BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 76.9%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NKTR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 127.0%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NKTR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -239.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NKTR vs VOR Key Questions & Quantitative Answers

As of Nov 16, 2026, Nektar Therapeutics (NKTR) captures the overall head-to-head institutional edge over Vor Biopharma Inc. (VOR) on higher Unified Composite conviction (61.1/100 BUY vs. 57.8/100 HOLD) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while VOR wins 3–2 across the 6-pillar growth and valuation breakdown. NKTR trades at $36.57 (34.0x Forward P/E, -239.3% operating margin) versus VOR at $19.26 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NKTR earns the overall head-to-head edge with a stronger Unified Composite Score (61.1/100 BUY vs. VOR 57.8/100 HOLD) and 1.10β · 48% Vol risk profile, whereas VOR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NKTR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3); meanwhile VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NKTR leads the Growth & Scale pillar: NKTR posts -9.3% YoY revenue growth and +0.0% YoY earnings growth on $55M TTM revenue (100.0% gross margin, -239.3% operating margin), compared with VOR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NKTR generates $55M in USD-normalized revenue versus N/A for VOR. In operating R&D and SG&A reinvestment, NKTR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VOR.

NKTR screens cheaper on headline valuation multiples. NKTR trades at 34.0x Forward P/E, 34.0x Trailing P/E, 0.31x PEG, and 24.0x EV/Revenue (unreported FCF margin), whereas VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NKTR (-35.8% ROE) versus VOR (-125.4% ROE) capital efficiency.

In options market volatility and institutional positioning, NKTR carries 76.9% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.10β · 48% Vol realized risk). By comparison, VOR carries 127.0% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.91β · 61% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.